ARCHIVES

As patients worry about COX-2 inhibitors, scientists and FDA review toxicity data.

This article is from The Cancer Letter archive.

Vol. 30 No. 40 | October 22, 2004

Download PDF Visit The Full Archive

Related Articles

NIH funds four centers to study breast cancer and the environment.

October 17, 2003

Avon, NABCO Accepting Grant Applications For Community-Based Breast Cancer Programs

June 9, 1995

In Brief: NCI’s Katz Named Director, Arthritis Institute; Hayden Promoted At Bristol-Myers Squibb

July 14, 1995

In Brief: NCAB To Hear NCOG Appeal; FDA Renege On New Toxicology Protocol, Holds Up INDs

April 24, 1981

Boyd Steps Down As DTP Director, Returns to Research

February 16, 1990

Two “optimists” present different visions for rapid progress in cancer research at American Association for Cancer Research annual meeting. Leland Hartwell advocates genome-like project for molecular diagnostics. Andrew von Eschenbach describes “fantasies, dreams, visions” becoming reality.

April 9, 2004